Towards mRNA therapeutics 2.0.
Innovative delivery systems and formulations are key to advancing mRNA therapeutics 2.0, enabling repeated administration and targeted organ delivery beyond the liver.
- Why it matters: Overcoming current barriers in mRNA drug development is crucial to unlock its full potential for treating a wide range of diseases, including rare conditions and cancers.
- What they did: The review analyzes clinical studies involving enzyme replacement, cancer immunotherapy, genome editing, and immune cell reprogramming, highlighting novel interdisciplinary approaches and delivery methods.
- The result: These advances could accelerate the development of safer, more effective mRNA therapies with broader organ targeting, paving the way for a new era of personalized medicine.